Bank of New York Mellon
TPTX

Bank of New York Mellon’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Bank of New York Mellon’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-155,302
Closed -$11.7M – 4637
2022
Q2 		$11.7M Sell
155,302
-52,804
-25% -$2.35M ﹤0.01% 1842
2022
Q1 		$5.59M Sell
208,106
-884
-0.4% -$29.7K ﹤0.01% 2361
2021
Q4 		$9.97M Sell
208,990
-9,492
-4% -$424K ﹤0.01% 2103
2021
Q3 		$14.5M Buy
218,482
+18,782
+9% +$1.34M ﹤0.01% 1913
2021
Q2 		$15.6M Buy
199,700
+42,742
+27% +$3.16M ﹤0.01% 1875
2021
Q1 		$14.8M Sell
156,958
-13,149
-8% -$1.56M ﹤0.01% 1876
2020
Q4 		$20.7M Buy
170,107
+17,071
+11% +$1.87M ﹤0.01% 1615
2020
Q3 		$13.4M Buy
153,036
+31,551
+26% +$2.2M ﹤0.01% 1696
2020
Q2 		$7.85M Buy
121,485
+17,109
+16% +$987K ﹤0.01% 1972
2020
Q1 		$4.66M Buy
104,376
+1,694
+2% +$90K ﹤0.01% 2105
2019
Q4 		$6.4M Buy
102,682
+55,833
+119% +$2.66M ﹤0.01% 2214
2019
Q3 		$1.76M Buy
46,849
+16,090
+52% +$700K ﹤0.01% 2816
2019
Q2 		$1.25M Buy
+30,759
New +$1.1M ﹤0.01% 3074

Bank of New York Mellon's TPTX Position: Q3 2022 in Review

Bank of New York Mellon sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 155,302 shares — an estimated $11.7M sold.

Bank of New York Mellon first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $20.7M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Bank of New York Mellon reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 155,302 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $11.7M.
  • Bank of New York Mellon first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • Bank of New York Mellon's Turning Point Therapeutics, Inc. Common Stock position peaked at $20.7M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Bank of New York Mellon's 13F filing for Q3 2022, filed 14 Nov 2022.